Emily S Tonorezos1,2, Jennifer S Ford3, Linwei Wang4, Kirsten K Ness5, Yutaka Yasui5, Wendy Leisenring6, Charles A Sklar7, Leslie L Robison5, Kevin C Oeffinger8, Paul C Nathan9, Gregory T Armstrong5, Kevin Krull5, Lee W Jones1,2. 1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Medicine, Weill Cornell Medical College, New York, New York. 3. Department of Psychology, Hunter College, City University of New York, New York, New York. 4. Department of Epidemiology and Public Health, British Columbia Center for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada. 5. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee. 6. Clinical Research Division and Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. 7. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York. 8. Duke Center for Onco-Primary Care, Duke Cancer Institute, Duke University, Durham, North Carolina. 9. Department of Hematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Childhood cancer survivors are at risk for adverse psychological outcomes. Whether exercise can attenuate this risk is unknown. METHODS: In total, 6199 participants in the Childhood Cancer Survivor Study (median age, 34.3 years [range, 22.0-54.0 years]; median age at diagnosis, 10.0 years [range, 0-21.0 years]) completed a questionnaire assessing vigorous exercise and medical/psychological conditions. Outcomes were evaluated a median of 7.8 years (range, 0.1-10.0 years) later and were defined as: symptom level above the 90th percentile of population norms for depression, anxiety, or somatization on the Brief Symptom Inventory-18; cancer-related pain; cognitive impairment using a validated self-report neurocognitive questionnaire; or poor health-related quality of life. Log-binomial regression estimated associations between exercise (metabolic equivalent [MET]-hours per week-1 ) and outcomes adjusting for cancer diagnosis, treatment, demographics, and baseline conditions. RESULTS: The prevalence of depression at follow-up was 11.4% (95% CI, 10.6%-12.3%), anxiety 7.4% (95% CI, 6.7%-8.2%) and somatization 13.9% (95% CI, 13.0%-14.9%). Vigorous exercise was associated with lower prevalence of depression and somatization. The adjusted prevalence ratio for depression was 0.87 (95% CI, 0.72-1.05) for 3 to 6 MET hours per week-1 , 0.76 (95% CI, 0.62-0.94) for 9 to 12 MET-hours per week-1 , and 0.74 (95% CI, 0.58-0.95) for 15 to 21 MET-hours per week-1 . Compared with 0 MET hours per week-1 , 15 to 21 MET-hours per week-1 were associated with an adjusted prevalence ratio of 0.79 (95% CI, 0.62-1.00) for somatization. Vigorous exercise also was associated with less impairment in the physical functioning, general health and vitality (Ptrend < .001), emotional role limitations (Ptrend = .02), and mental health (Ptrend = .02) domains as well as higher cognitive function in the domains of task completion, organization, and working memory (P < .05 for all), but not in the domain of cancer pain. CONCLUSIONS: Vigorous exercise is associated with less psychological burden and cognitive impairment in childhood cancer survivors.
BACKGROUND: Childhood cancer survivors are at risk for adverse psychological outcomes. Whether exercise can attenuate this risk is unknown. METHODS: In total, 6199 participants in the Childhood Cancer Survivor Study (median age, 34.3 years [range, 22.0-54.0 years]; median age at diagnosis, 10.0 years [range, 0-21.0 years]) completed a questionnaire assessing vigorous exercise and medical/psychological conditions. Outcomes were evaluated a median of 7.8 years (range, 0.1-10.0 years) later and were defined as: symptom level above the 90th percentile of population norms for depression, anxiety, or somatization on the Brief Symptom Inventory-18; cancer-related pain; cognitive impairment using a validated self-report neurocognitive questionnaire; or poor health-related quality of life. Log-binomial regression estimated associations between exercise (metabolic equivalent [MET]-hours per week-1 ) and outcomes adjusting for cancer diagnosis, treatment, demographics, and baseline conditions. RESULTS: The prevalence of depression at follow-up was 11.4% (95% CI, 10.6%-12.3%), anxiety 7.4% (95% CI, 6.7%-8.2%) and somatization 13.9% (95% CI, 13.0%-14.9%). Vigorous exercise was associated with lower prevalence of depression and somatization. The adjusted prevalence ratio for depression was 0.87 (95% CI, 0.72-1.05) for 3 to 6 MET hours per week-1 , 0.76 (95% CI, 0.62-0.94) for 9 to 12 MET-hours per week-1 , and 0.74 (95% CI, 0.58-0.95) for 15 to 21 MET-hours per week-1 . Compared with 0 MET hours per week-1 , 15 to 21 MET-hours per week-1 were associated with an adjusted prevalence ratio of 0.79 (95% CI, 0.62-1.00) for somatization. Vigorous exercise also was associated with less impairment in the physical functioning, general health and vitality (Ptrend < .001), emotional role limitations (Ptrend = .02), and mental health (Ptrend = .02) domains as well as higher cognitive function in the domains of task completion, organization, and working memory (P < .05 for all), but not in the domain of cancer pain. CONCLUSIONS: Vigorous exercise is associated with less psychological burden and cognitive impairment in childhood cancer survivors.
Authors: Shinichiro Mizumatsu; Michelle L Monje; Duncan R Morhardt; Radoslaw Rola; Theo D Palmer; John R Fike Journal: Cancer Res Date: 2003-07-15 Impact factor: 12.701
Authors: Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Toana Kawashima; Melissa M Hudson; Anna T Meadows; Debra L Friedman; Neyssa Marina; Wendy Hobbie; Nina S Kadan-Lottick; Cindy L Schwartz; Wendy Leisenring; Leslie L Robison Journal: N Engl J Med Date: 2006-10-12 Impact factor: 176.079
Authors: Leslie L Robison; Ann C Mertens; John D Boice; Norman E Breslow; Sarah S Donaldson; Daniel M Green; Frederic P Li; Anna T Meadows; John J Mulvihill; Joseph P Neglia; Mark E Nesbit; Roger J Packer; John D Potter; Charles A Sklar; Malcolm A Smith; Marilyn Stovall; Louise C Strong; Yutaka Yasui; Lonnie K Zeltzer Journal: Med Pediatr Oncol Date: 2002-04
Authors: Melissa M Hudson; Ann C Mertens; Yutaka Yasui; Wendy Hobbie; Hegang Chen; James G Gurney; Mark Yeazel; Christopher J Recklitis; Neyssa Marina; Leslie R Robison; Kevin C Oeffinger Journal: JAMA Date: 2003-09-24 Impact factor: 157.335
Authors: AnnaLynn M Williams; Sedigheh Mirzaei Salehabadi; Mengqi Xing; Nicholas S Phillips; Matthew J Ehrhardt; Rebecca Howell; Yutaka Yasui; Kevin C Oeffinger; Todd Gibson; Eric J Chow; Wendy Leisenring; Deokumar Srivastava; Melissa M Hudson; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: Blood Date: 2022-05-19 Impact factor: 25.476
Authors: Emily Barlow-Krelina; Yan Chen; Yutaka Yasui; Christine Till; Todd M Gibson; Kirsten K Ness; Wendy M Leisenring; Rebecca M Howell; Paul C Nathan; Kevin C Oeffinger; Leslie L Robison; Gregory T Armstrong; Kevin R Krull; Kim Edelstein Journal: J Clin Oncol Date: 2020-04-24 Impact factor: 44.544
Authors: Neel S Bhatt; Malek J Baassiri; Wei Liu; Nickhill Bhakta; Wassim Chemaitilly; Matthew J Ehrhardt; Hiroto Inaba; Kevin Krull; Kirsten K Ness; Jeffrey E Rubnitz; Deokumar Srivastava; Leslie L Robison; Melissa M Hudson; Daniel A Mulrooney Journal: Leukemia Date: 2021-01-25 Impact factor: 11.528
Authors: Hanne C Lie; Sigmund Anderssen; Corina Silvia Rueegg; Truls Raastad; May Grydeland; Lene Thorsen; Trine Stensrud; Elisabeth Edvardsen; Marie Hamilton Larsen; Ingrid Kristin Torsvik; Lars Peder Bovim; Miriam Götte; Päivi Maria Lähteenmäki; Susi Kriemler; Hanne Bækgaard Larsen; Martin Kaj Fridh; Kristin Ørstavik; Henrik Brun; Iren Matthews; Else Hornset; Ellen Ruud Journal: JMIR Res Protoc Date: 2022-03-08
Authors: Alessandro de Sire; Lorenzo Lippi; Antonio Ammendolia; Carlo Cisari; Konstantinos Venetis; Elham Sajjadi; Nicola Fusco; Marco Invernizzi Journal: J Pers Med Date: 2021-12-14